Eir Ventures leads seed funding round for Synklino

Financial terms of the round were not disclosed. 

Synklino, established two years ago, will use the funds to advance its lead programme in clinical testing and expand its management team. 

The company's drug, SYN002, has the potential to eliminate cytomegalovirus (CMV), a virus that infects most people in adulthood and is involved in causing infectious complications following transplantation.

Company
Founded in 2017 and based in Copenhagen, Synklino is a spinout from the University of Copenhagen and the Technical University of Denmark that was established to develop therapies against viral infections.

Synklino is incubated at the BioInnovation Institute in its Creation House programme. It currently has 10 employees, according to its LinkedIn profile. 

People
Synklino – Thomas Kledal (co-founder, CEO). 
Eir Ventures – Stephan Christgau (founding partner).
Vaekstfonden – Lene Gerlach (investment manager).

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Early-stage
• Nordics
• Healthcare
• Denmark
• Nordic venture